A Study to Evaluate Subjects With Turner Syndrome Treated With Growth Hormone

Characterization of Subjects With Turner Syndrome Treated With Growth Hormone in the National Cooperative Growth Study (NCGS)

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT00097552

Enrollment

1696

Registered

2004-11-25

Start date

1997-05-31

Completion date

2010-07-31

Last updated

2012-11-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Turner Syndrome

Brief summary

This study is a multicenter, open-label, observational, postmarketing surveillance study of Genentech growth hormone (GH) products in the treatment of girls with Turner syndrome in the United States and Canada.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

FEMALE

Age

No minimum to 17 Years

Healthy volunteers

Inclusion criteria

* Are girls with Turner syndrome who are being or will be treated with Nutropin, Nutropin AQ, or Protropin * Are willing to keep follow-up appointments throughout study participation * Are girls with Turner syndrome who have submitted Form 4 upon discontinuation and may also submit Form 9

Exclusion criteria

* Have Noonan syndrome * Subjects treated within the last 6 months with a non-Genentech GH preparation * Have closed epiphyses prior to NCGS enrollment * Have active neoplasia

Outcome results